La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Teyi Pharmaceutical GroupLtd Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Teyi Pharmaceutical GroupLtd ha un patrimonio netto totale di CN¥1.8B e un debito totale di CN¥453.0M, che porta il suo rapporto debito/patrimonio netto a 24.8%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥2.4B e CN¥579.8M. L'EBIT di Teyi Pharmaceutical GroupLtd è CN¥122.6M rendendo il suo rapporto di copertura degli interessi -69.7. Ha liquidità e investimenti a breve termine pari a CN¥514.2M.

Informazioni chiave

24.8%

Rapporto debito/patrimonio netto

CN¥453.00m

Debito

Indice di copertura degli interessi	-69.7x
Contanti	CN¥514.25m
Patrimonio netto	CN¥1.83b
Totale passività	CN¥579.82m
Totale attività	CN¥2.41b

Aggiornamenti recenti sulla salute finanziaria

We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Can Stay On Top Of Its Debt

Jun 06

Recent updates

We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Can Stay On Top Of Its Debt

Jun 06

Why Teyi Pharmaceutical GroupLtd's (SZSE:002728) Shaky Earnings Are Just The Beginning Of Its Problems

Apr 26

Teyi Pharmaceutical Group Co.,Ltd's (SZSE:002728) Shares Bounce 29% But Its Business Still Trails The Market

Mar 06

Here's Why We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Is Well Worth Watching

Feb 27

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( CN¥965.1M ) di 002728 superano le sue passività a breve termine ( CN¥544.8M ).

Passività a lungo termine: Le attività a breve termine di 002728 ( CN¥965.1M ) superano le sue passività a lungo termine ( CN¥35.0M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 002728 ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di 002728 si è ridotto da 93.8% a 24.8% negli ultimi 5 anni.

Copertura del debito: Il debito di 002728 è ben coperto dal flusso di cassa operativo ( 21.5% ).

Copertura degli interessi: 002728 matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.

Teyi Pharmaceutical GroupLtd Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Can Stay On Top Of Its Debt

Recent updates

Now 24% overvalued

Now 20% overvalued

Teyi Pharmaceutical Group Co.,Ltd to Report First Half, 2024 Results on Jul 19, 2024

Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) announces an Equity Buyback for CNY 120 million worth of its shares.

We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Can Stay On Top Of Its Debt

Why Teyi Pharmaceutical GroupLtd's (SZSE:002728) Shaky Earnings Are Just The Beginning Of Its Problems

Investor sentiment deteriorates as stock falls 15%

First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.33 in 1Q 2023)

Teyi Pharmaceutical Group Co.,Ltd to Report Q1, 2024 Results on Apr 20, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 22% overvalued

Teyi Pharmaceutical Group Co.,Ltd, Annual General Meeting, Mar 28, 2024

Teyi Pharmaceutical Group Co.,Ltd, Annual General Meeting, Mar 28, 2024

Teyi Pharmaceutical Group Co.,Ltd's (SZSE:002728) Shares Bounce 29% But Its Business Still Trails The Market

Here's Why We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Is Well Worth Watching

Investor sentiment deteriorates as stock falls 18%

High number of new and inexperienced directors

Teyi Pharmaceutical Group Co.,Ltd to Report Fiscal Year 2023 Results on Mar 08, 2024

Investor sentiment improves as stock rises 21%

Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.11 in 3Q 2022)

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.051 in 2Q 2022)

Teyi Pharmaceutical Group Co.,Ltd Announces Final Dividend on A Shares for the Year 2022, Payable on May 26, 2023

Teyi Pharmaceutical Group Co.,Ltd Approves Cash Dividend (Tax Included) for 2022

Full year 2022 earnings released: EPS: CN¥0.80 (vs CN¥0.62 in FY 2021)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 24%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.14 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.071 (vs CN¥0.17 in 2Q 2021)

High number of new directors

Teyi Pharmaceutical Group Co.,Ltd Announces Management Appointments

Investor sentiment improved over the past week

Teyi Pharmaceutical Group Co.,Ltd Announces Final Cash Dividend on A Shares for the Year 2021, Payable on May 10, 2022

First quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.20 in 1Q 2021)

Investor sentiment deteriorated over the past week

Teyi Pharmaceutical Group Co.,Ltd Approves Cash Dividend (Tax Included) for the Year 2021

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.007 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.021 in 2Q 2020)

Investor sentiment improved over the past week

Teyi Pharmaceutical Group Co.,Ltd Proposes 2020 Final Profit Distribution Plan, Payable on 03 June 2021

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.22 (vs CN¥0.85 in FY 2019)

New 90-day low: CN¥10.51

New 90-day low: CN¥12.39

Teyi Pharmaceutical Group Co.,Ltd to Report Q3, 2020 Results on Oct 27, 2020

Yueke Zhijing cancelled the acquisition of 5% stake in Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) from Xu Weigao, Xu Hengqing and Xu Lifang.

New 90-day low - CN¥13.52

Earnings released

Teyi Pharmaceutical Group Co.,Ltd to Report First Half, 2020 Results on Aug 26, 2020

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane